- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03748641
Un estudio de niraparib en combinación con acetato de abiraterona y prednisona versus acetato de abiraterona y prednisona para el tratamiento de participantes con cáncer de próstata metastásico (MAGNITUDE)
Un estudio de fase 3, aleatorizado, controlado con placebo, doble ciego de niraparib en combinación con acetato de abiraterona y prednisona versus acetato de abiraterona y prednisona en sujetos con cáncer de próstata metastásico
The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate plus prednisone (AAP) compared to AAP and placebo.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 3
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Braunschweig, Alemania, 38126
- Städtisches Klinikum Braunschweig gGmbH - Standort Salzdahlumer
-
Duisburg, Alemania, 47179
- Urologicum Duisburg
-
Homburg, Alemania, 66424
- Universitätsklinikum des Saarlandes
-
Magdeburg, Alemania, 39120
- Universitätsklinikum Otto-von-Guericke-Universität Magdeburg
-
Münster, Alemania, 48149
- Universitaetsklinikum Muenster
-
Nürtingen, Alemania, 72622
- Studienpraxis Urologie Drs. Feyerabend
-
-
-
-
-
Buenos Aires, Argentina, C1118AAT
- Hospital Aleman
-
Buenos Aires, Argentina, C1426AGE
- Centro Oncológico Korben
-
Buenos Aires, Argentina, C1431FWN
- CEMIC Saavedra
-
Ciudad Automoma Buenos Aires, Argentina, C1120AAT
- Centro de Urologia (CDU)
-
Córdoba, Argentina, X5016KEH
- Hospital Privado Centro Medico de Cordoba
-
Córdoba, Argentina, 5000
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Mar del Plata, Argentina, B7602CBM
- Hospital Privado de Comunidad
-
Mar del Plata, Argentina, B7600FZN
- Instituto de Investigaciones Clinicas Mar del Plata
-
Pergamino, Argentina, B2700CPM
- Centro de Investigacion Pergamino SA
-
Rosario, Argentina, 2000
- Sanatorio Britanico de Rosario
-
Rosario, Argentina, S2000SDV
- Sanatorio Parque
-
San Salvador de Jujuy, Argentina, Y4600AFW
- ARS Médica
-
-
-
-
-
Adelaide, Australia, 5000
- Royal Adelaide Hospital
-
Benowa, Australia, 4217
- Pindara Private Hospital
-
Birtinya, Australia, 4575
- Sunshine Coast University Hospital
-
Brisbane, Australia, 4102
- Princess Alexandra Hospital
-
Darlinghurst, Australia, 2010
- St Vincent s Hospital Sydney
-
Hobart, Australia, 7000
- Royal Hobart Hospital
-
Macquarie University, Australia, 2109
- Macquarie University
-
Malvern, Australia, 3144
- Eye Surgery Associates
-
Melbourne, Australia, 3000
- Peter MacCallum Cancer Centre
-
Murdoch, Australia, 6150
- Fiona Stanley Hospital
-
Nedlands, Australia, 6009
- Hollywood Private Hospital
-
Randwick, Australia, 2031
- Prince Of Wales Hospital
-
Wahroonga, Australia, 2076
- Sydney Adventist Hospital
-
Wollongong, Australia, 2500
- Wollongong Private Hospital
-
-
-
-
-
Barretos, Brasil, 14784-400
- Fundacao Pio XII
-
Belo Horizonte, Brasil, 30130-090
- PERSONAL Oncologia de Precisao e Personalizada
-
Brasília, Brasil, 7020-730
- Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia
-
Curitiba, Brasil, 80810 050
- CIONC Centro Integrado de Oncologia de Curitiba
-
Fortaleza, Brasil, 60 810180
- Pronutrir
-
Goiânia, Brasil, 74605-070
- Associacao de Combate ao Cancer em Goias - Hospital de Cancer Araujo Jorge
-
Ijuí, Brasil, 98700-000
- Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
-
Ipatinga, Brasil, 35162 189
- Fundacao Sao Francisco Xavier
-
Joinville, Brasil, 89201-260
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Maceió, Brasil, 57052-765
- Medradius Clinica de Medicina Nuclear e Radiologia de Maceio Ltda.
-
Natal, Brasil, 59062 000
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasil, 90020-090
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, Brasil, 90160-093
- Hospital Ernesto Dornelles
-
Rio de Janeiro, Brasil, 20551-030
- Universidade do Estado do Rio de Janeiro - UERJ
-
Rio de Janeiro, Brasil, 22250 905
- Oncoclinicas Rio de Janeiro S A
-
Rio de Janeiro, Brasil, 22775 001
- Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI)
-
Rio de Janeiro, Brasil, 20230 130
- Ministerio da Saude Instituto Nacional do Cancer
-
Salvador, Brasil, 40050-410
- Hospital Santa Isabel
-
Santo André, Brasil, 09060-650
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
Sorocaba, Brasil, 18030-005
- IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
-
São Paulo, Brasil, 04014-002
- Núcleo de Pesquisa São Camilo
-
São Paulo, Brasil, 01236-030
- Instituto de Ensino e Pesquisa São Lucas
-
São Paulo, Brasil, 04502-001
- Instituto D Or de Pesquisa e Ensino IDOR
-
São Paulo, Brasil, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasil, 04039-004
- Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE
-
São Paulo, Brasil, 01246 000
- Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasil, 01221-020
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo, Brasil, 01421-000
- Hospital Alemao Oswaldo Cruz
-
Três Lagoas, Brasil, 79601-001
- Instituto Do Cancer Brasil
-
-
-
-
-
Burgas, Bulgaria, 8001
- MHAT Deva Maria
-
Pleven, Bulgaria, 5800
- UMHAT 'Dr. Georgi Stranski', EAD
-
Plovdiv, Bulgaria, 4004
- Complex Oncology Center - Plovdiv EOOD
-
Sofia, Bulgaria, 1756
- Specialized Hospital for Active Treatment in Oncology EAD
-
Varna, Bulgaria, 9010
- SHATOD 'Dr. Marko Antonov Markov'
-
Vratsa, Bulgaria, 3001
- Comprehensive Cancer Center
-
-
-
-
-
Aalst, Bélgica, 9300
- OLV Ziekenhuis Aalst
-
Antwerp, Bélgica, 2610
- ZAS Augustinus
-
Charleroi, Bélgica, 6000
- Grand Hopital de Charleroi, site Notre Dame
-
Ghent, Bélgica, 9000
- AZ Maria Middelares
-
Liège, Bélgica, B-4000
- Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
-
Merksem, Bélgica, 2170
- ZNA Jan Palfijn
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2V 1P9
- Southern Alberta Institute of Urology / Prostate Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- British Columbia Cancer Agency BCCA Vancouver Centre
-
Victoria, British Columbia, Canadá, V8R 6V5
- British Columbia Cancer Agency Vancouver Island Centre
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 4A6
- McMaster Institute of Urology
-
Kingston, Ontario, Canadá, K7L 3N6
- Cancer Centre of Southeastern Ontario (Kingston Regional Cancer Centre)
-
Toronto, Ontario, Canadá, M5G2M9
- Princess Margaret Cancer Centre University Health Network
-
Toronto, Ontario, Canadá, M4N 3M5
- Sunnybrook Health Sciences Center
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 0A9
- Centre de Recherche du CHUM
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canadá, S7N 4H4
- Saskatoon Cancer Centre
-
-
-
-
-
Hradec Králove, Chequia, 500 05
- Fakultni nemocnice Hradec Kralove
-
Liberec, Chequia, 460 63
- Krajská nemocnice Liberec
-
Olomouc, Chequia, 77900
- Uromedical Center s.r.o.
-
Pardubice, Chequia, 53203
- Multiscan s.r.o.
-
Pilsen, Chequia, 305 99
- Fakultni nemocnice Plzen, Urologicka klinika
-
Prague, Chequia, 120 00
- Urologicka klinika 1 LF UK a VFN
-
Prague, Chequia, 140 59
- Thomayerova nemocnice, Onkologicka klinika
-
Uherské Hradiště, Chequia, 68668
- Uherskohradistska nemocnice a.s.
-
-
-
-
-
Busan, Corea del Sur, 49241
- Pusan National University Hospital
-
Daegu, Corea del Sur, 41404
- Kyungpook National University Chilgok Hospital
-
Daegu, Corea del Sur, 42601
- Keimyung University Dongsan Hospital
-
Daejeon, Corea del Sur, 35015
- Chungnam National University Hospital
-
Gwangju, Corea del Sur, 61469
- Chonnam National University Hospital
-
Gyeonggi-do, Corea del Sur, 10408
- National Cancer Center
-
Gyeonggi-do, Corea del Sur, 443-721
- Ajou University Hospital
-
Seongnam-si, Corea del Sur, 13620
- Seoul National University Bundang Hospital
-
Seoul, Corea del Sur, 03080
- Seoul National University Hospital
-
Seoul, Corea del Sur, 05505
- Asan Medical Center
-
Seoul, Corea del Sur, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, Corea del Sur, 06351
- Samsung Medical Center
-
Seoul, Corea del Sur, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
Seoul, Corea del Sur, 06273
- Gangnam Severance Hospital, Yonsei University Health System
-
-
-
-
-
A Coruña, España, 15006
- Hospital Juan Canalejo
-
Barcelona, España, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, España, 08003
- Hosp. Del Mar
-
Barcelona, España, 08036
- Hosp Clinic de Barcelona
-
Jerez de la Frontera, España, 11407
- Hosp. de Jerez de La Frontera
-
Madrid, España, 28040
- Hosp. Clinico San Carlos
-
Madrid, España, 28034
- Hosp. Univ. Ramon Y Cajal
-
Málaga, España, 29010
- Hosp Virgen de La Victoria
-
Pozuelo de Alarcón, España, 28223
- Hosp. Quiron Madrid Pozuelo
-
Sabadell, España, 08208
- Corporacio Sanitari Parc Tauli
-
Santander, España, 39008
- Hosp. Univ. Marques de Valdecilla
-
Valencia, España, 46026
- Hosp. Univ. I Politecni La Fe
-
-
-
-
Alabama
-
Homewood, Alabama, Estados Unidos, 35209
- Urology Centers Of Alabama
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Mayo Clinic Arizona
-
Tucson, Arizona, Estados Unidos, 85741
- Urological Associates of Southern Arizona, P.C.
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72211
- Arkansas Urology
-
-
California
-
Riverside, California, Estados Unidos, 92505
- Kaiser Permanente
-
San Bernardino, California, Estados Unidos, 92404
- San Bernardino Urological Associates
-
San Francisco, California, Estados Unidos, 94158
- University of California San Francisco
-
Santa Barbara, California, Estados Unidos, 93105
- Sansum Clinic Pharm
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80211
- The Urology Center of Colorado
-
Lakewood, Colorado, Estados Unidos, 80228
- Colorado Clinical Research
-
-
Connecticut
-
West Haven, Connecticut, Estados Unidos, 06516
- VA Connecticut Healthcare
-
-
Florida
-
Bay Pines, Florida, Estados Unidos, 33744
- Bay Pines VA Healthcare System
-
Daytona Beach, Florida, Estados Unidos, 32114
- Advanced Urology Institute
-
Jacksonville, Florida, Estados Unidos, 32209
- University of Florida Health Jacksonville
-
Jacksonville, Florida, Estados Unidos, 32224
- Mayo Clinic - Division Of Hematology/oncology
-
-
Illinois
-
Hines, Illinois, Estados Unidos, 60141
- Veterans Affairs Medical Ctr
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46825
- Fort Wayne Medical Oncology and Hematology
-
Jeffersonville, Indiana, Estados Unidos, 47130
- First Urology
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Medical Center
-
-
Kentucky
-
Louisville, Kentucky, Estados Unidos, 40202
- Norton Healthcare
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20817
- Rcca Md, Llc
-
Towson, Maryland, Estados Unidos, 21204
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General
-
-
Michigan
-
Troy, Michigan, Estados Unidos, 48084
- Michigan Institute of Urology
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64128
- Kansas City Veterans Affairs Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Nebraska Cancer Specialists
-
Omaha, Nebraska, Estados Unidos, 68114
- Adult Pediatric Urology & Urogynecology, P.C
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Comprehensive Cancer Centers of Nevada
-
-
New Jersey
-
Mount Laurel, New Jersey, Estados Unidos, 08054
- Delaware Valley Urology, LLC
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- New York Oncology Hematology
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai - The Derald H. Ruttenberg
-
Syracuse, New York, Estados Unidos, 13210
- Upstate Cancer Center
-
-
Ohio
-
Middleburg Heights, Ohio, Estados Unidos, 44130
- Helios Clinical Research, LLC
-
-
Oregon
-
Springfield, Oregon, Estados Unidos, 97477
- Oregon Urology Institute
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Estados Unidos, 19004
- MidLantic Urology
-
Lancaster, Pennsylvania, Estados Unidos, 17604
- Lancaster Urology
-
Pittsburgh, Pennsylvania, Estados Unidos, 15240
- VA Pittsburgh
-
-
South Carolina
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37209
- Urology Associates
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- University of Texas MD Anderson Cancer Center
-
Houston, Texas, Estados Unidos, 77027
- Houston Metro Urology
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists
-
-
Virginia
-
Salem, Virginia, Estados Unidos, 80113
- Salem VA Medical Center
-
Virginia Beach, Virginia, Estados Unidos, 23462
- Urology of Virginia, PLCC
-
-
Washington
-
Tacoma, Washington, Estados Unidos, 98405
- NorthWest Medical Specialties, PLLC
-
-
-
-
-
Besançon, Francia, 25030
- CHRU De Besancon
-
Bordeaux, Francia, 33000
- Institut Bergonie
-
Clermont-Ferrand, Francia, 63011
- Centre Jean Perrin
-
Lyon, Francia, 69008
- Centre Leon Berard
-
Montpellier, Francia, 34298
- Institut Regional du Cancer de Montpellier Val d'Aurelle
-
Nancy, Francia, 54100
- Polyclinique de Gentilly
-
Nice, Francia, 06189
- Centre Antoine Lacassagne
-
Paris, Francia, 75908
- Hopital Europeen Georges-Pompidou
-
Saint-Herblain, Francia, 44805
- Institut de Cancerologie de l Ouest ICO
-
Saint-Mandé, Francia, 94163
- HIA Begin
-
Strasbourg, Francia, 67098
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
-
-
-
-
-
Budapest, Hungría, 1082
- Semmelweis Egyetem, Urológia Klinika
-
Budapest, Hungría, 1122
- Országos Onkológiai Intézet, C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály
-
Debrecen, Hungría, 4032
- Debreceni Egyetem Klinikai Kozpont
-
Gyula, Hungría, 5700
- Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz
-
Nyíregyháza, Hungría, 4400
- Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz
-
Pécs, Hungría, 7621
- Uro-Clin Kft.
-
Szeged, Hungría, 6720
- Szegedi Tudomanyegyetem
-
Szeged, Hungría, 6725
- Szegedi Tudomanyegyetem 1
-
Szombathely, Hungría, 9700
- Markusovszky Egyetemi Oktatokorhaz
-
-
-
-
-
Beer Yaakov, Israel, 60930
- Asaf Harofe Medical Center
-
Haifa, Israel, 31096
- Rambam Health Care Campus
-
Petah Tikva, Israel, 49100
- Rabin Medical Center
-
Ramat Gan, Israel, 52621
- Sheba Medical Center Tel Hashomer
-
-
-
-
-
Faenza, Italia, 48018
- AUSL Romagna - Ospedale di Faenza
-
Milan, Italia, 20132
- Ospedale San Raffaele
-
Milan, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda
-
Naples, Italia, 80131
- Oncologia Medica A - Ist Naz Tumori G Pascale
-
Padova, Italia, 35128
- Istituto Oncologico Veneto Iov Irccs Padova
-
Parma, Italia, 43126
- Oncologia Medica - Azienda Ospedaliero Universitaria Di Parma
-
Perugia, Italia, 06132
- Ospedale S. Maria Della Misericordia Centro Operativo Studi Clinici SC Oncologia Medica
-
Pisa, Italia, 56126
- Azienda Ospedaliero Universitaria Pisana
-
Roma, Italia, 00168
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Roma, Italia, 128
- Campus Bio Medico di Roma
-
Terni, Italia, 5100
- Azienda Ospedaliera S. Maria Terni
-
Torino, Italia, 10126
- A.O.U. Città della Salute e della Scienza
-
Trento, Italia, 38122
- Ospedale Santa Chiara Trento
-
-
-
-
-
George Town, Malasia, 10990
- Hospital Pulau Pinang
-
Johor Bahru, Malasia, 81100
- Hospital Sultan Ismail
-
Kota Kinabalu, Malasia, 88996
- Hospital Likas
-
Kuala Lumpur, Malasia, 50586
- Hospital Kuala Lumpur
-
Kuala Lumpur, Malasia, 59100
- University Malaya Medical Centre
-
Kuching, Malasia, 93586
- Sarawak General Hospital
-
-
-
-
-
Aguascalientes, México, 20010
- iBiomed Research Unit
-
Durango, México, 34000
- Consultorio de Especialidad en Urologia Privado
-
Mexico City, México, 03100
- Mexico Centre for Clinical Research, S.A. de C.V.
-
Monterrey, México, 64710
- Avix Investigacion Clinica S C
-
Zapopan, México, 45040
- Consultorio Privado
-
-
-
-
-
Amsterdam, Países Bajos, 1066 CX
- Antoni van Leeuwenhoek
-
Groningen, Países Bajos, 9713 GZ
- Universitair Medisch Centrum Groningen
-
Leidschendam, Países Bajos, 2262 BA
- MC Haaglanden Lok Antoniushove - Afd.Interne - INT
-
Nieuwegein, Países Bajos, 3430EM
- St. Antonius Ziekenhuis (St. Antonius Hospital)
-
Nijmegen, Países Bajos, 6532 SZ
- Canisius-Wilhelminaziekenhuis
-
Rotterdam, Países Bajos, 3075 EA
- Erasmus MC
-
Sittard-Geleen, Países Bajos, 6162 BG
- Zuyderland Medical Center
-
-
-
-
-
Bydgoszcz, Polonia, 85 094
- Szpital Uniwersytecki NR 1 IM Dr Antoniego Jurasza
-
Bydgoszcz, Polonia, 85 796
- Centrum Onkologii im Prof F Lukaszczyka
-
Gdansk, Polonia, 80 214
- Uniwersyteckie Centrum Kliniczne
-
Gdynia, Polonia, 81 519
- Szpitale Pomorskie Sp z o o
-
Lodz, Polonia, 93-509
- Wojewodzki Szpital Specjalistyczny im. M. Kopernika w Lodzi
-
Siedlce, Polonia, 08-110
- Urologica Praktyka Lekarska Adam Marcheluk
-
Szczecin, Polonia, 70 111
- Pomorski Uniwersytet Medyczny w Szczecinie
-
Warsaw, Polonia, 02-781
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Wroclaw, Polonia, 53 413
- Dolnoslaskie Centrum Onkologii
-
-
-
-
-
Beijing, Porcelana, 100730
- Beijing Hospital
-
Beijing, Porcelana, 100191
- Peking University Third Hospital
-
Beijing, Porcelana, 100050
- Beijing Friendship Hospital
-
Beijing, Porcelana, 100034
- Peking University First Hospital
-
Beijing, Porcelana, 100021
- Cancer Hospital Chinese Academy of Medical Sciences
-
Beijing, Porcelana, 100142
- Beijing Cancer Hospital of Peking University
-
Chengdu, Porcelana, 610072
- Sichuan Provincial Peoples Hospital
-
Chongqing, Porcelana, 400030
- Chongqing University Cancer Hospital
-
Chongqing, Porcelana, 400025
- Southwest Hospital, The Third Military Medical University
-
Fuzhou, Porcelana, 350001
- Fujian Medical University Union Hospital
-
Guangzhou, Porcelana, 510180
- Guangzhou First Municipal People's Hospital
-
Guangzhou, Porcelana, 510120
- Sun Yat-Sen Memorial Hospital Sun Yat-sen University
-
Nanjing, Porcelana, 210009
- Jiangsu Cancer Hospital
-
Nanjing, Porcelana, 210008
- Nanjing Drum Tower Hospital
-
Ningbo, Porcelana, 315010
- Drug clinical trial ethics committee of Ningbo First Hospital
-
Shanghai, Porcelana, 200032
- Fudan University Shanghai Cancer Center
-
Shanghai, Porcelana, 200040
- Huashan Hospital Fudan University
-
Shanghai, Porcelana, 200001
- Renji Hospital, Shanghai Jiaotong University School of Medicine
-
Shanghai, Porcelana, 200040
- ShangHai Huadong Hospital
-
Shanghai, Porcelana, 200240
- The Fifth People's Hospital of Shanghai, Fudan University
-
Suzhou, Porcelana, 215006
- The First Affiliated Hospital of Soochow University
-
Tianjin, Porcelana, 300060
- Tianjin Medical University Cancer Hospital
-
Wuhan, Porcelana, 430014
- The Central Hospital of Wuhan
-
Wuhan, Porcelana, 430030
- Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Wuxi, Porcelana, 214023
- Wuxi People s Hospital
-
Xi'an, Porcelana, 710061
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Coimbra, Portugal, 3000-075
- Instituto Portugues de Oncologia de Coimbra Francisco Gentil, EPE
-
Coimbra, Portugal, 3000-075
- Hospitais da universidade de Coimbra
-
Lisbon, Portugal, 1400-038
- Champalimaud Foundation Champalimaud Centre
-
Lisbon, Portugal, 1649-035
- Centro Hospitalar Lisboa Norte EPE Hosp. Santa Maria
-
Porto, Portugal, 4099-001
- H. Santo António - Centro Hospitalar do Porto
-
-
-
-
-
San Juan, Puerto Rico, 00921
- VA Caribbean Healthcare System
-
-
-
-
-
Blackburn, Reino Unido, BB2 3HH
- Royal Blackburn Hospital
-
Lancaster, Reino Unido, LA1 4RP
- Royal Lancaster Infirmary
-
London, Reino Unido, WC1E 6DD
- UCL Cancer Institute
-
Torquay, Reino Unido, TQ2 7AA
- Torbay Hospital-Devon
-
Truro, Reino Unido, TR1 3LJ
- Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital
-
Wolverhampton, Reino Unido, WV10 0QP
- New Cross Hospital
-
-
-
-
-
Barnaul, Rusia, 656045
- Altai Regional Oncology Dispensary
-
Ivanovo, Rusia, 153040
- Ivanovo Regional Oncology Dispensary
-
Kursk, Rusia, 305524
- GUZ Kursk Regional Oncology Dispensary
-
Moscow, Rusia, 117997
- Russian Scientific Center of Roentgenoradiology
-
Moscow, Rusia, 125130
- Moscow City Clinical Hospital # 62
-
Nizhny Novgorod, Rusia, 603000
- Clinical Diagnostic Centre of Nizhny Novgorod Region
-
Omsk, Rusia, 644013
- Clinical Oncology Dispensary
-
Pyatigorsk, Rusia, 357500
- LLC Novaya Clinica
-
Pyatigorsk, Rusia, 357502
- Pyatigorsk Interdistrict Oncology Dispensary
-
Saint Petersburg, Rusia, 196603
- Private Medical Institution Euromedservice
-
Saint Petersburg, Rusia, 197758
- Russian Scientific Center of Radiology and Surgical Technologies
-
Saint Petersburg, Rusia, 191104
- Leningrad Regional Oncology Dispensary
-
Saransk, Rusia, 430032
- Republican Oncology Dispensary
-
Sochi, Rusia, 354057
- Oncologic Dispensary No.2
-
Tambov, Rusia, 392013
- Tambov Regional Oncology Clinical Dispansary
-
Tomsk, Rusia, 634050
- Tomsk Cancer Research Institute
-
Tyumen, Rusia, 625000
- Medical-sanitary unit 'Neftyanik'
-
Vologda, Rusia, 160012
- Vologda Regional Oncological Dispensary
-
-
-
-
-
Johannesburg, Sudáfrica, 1619
- Clinresco Centres Pty Ltd
-
Pretoria, Sudáfrica, 0001
- Clinical Research Unit
-
-
-
-
-
Stockholm, Suecia, 171 76
- Karolinska Universitetssjukhuset Solna
-
Stockholm, Suecia, 11883
- Sodersjukhuset
-
Uppsala, Suecia, 751 85
- Akademiska Sjukhuset
-
-
-
-
-
Kaohsiung City, Taiwán, 807
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung, Taiwán, 40705
- Taichung Veterans General Hospital
-
Taichung, Taiwán, 403
- China Medical University Hospital
-
Taichung, Taiwán, 435
- Tungs' Taichung MetroHarbor Hospital
-
Tainan, Taiwán, 710
- Chi Mei Medical Center Yong Kang
-
Taipei, Taiwán, 100
- National Taiwan University Hospital
-
Taipei, Taiwán, 11217
- Taipei Veterans General Hospital
-
Taoyuan, Taiwán, 33305
- Chang Gung Memorial Hospital
-
-
-
-
-
Adana, Turquía (Türkiye), 01330
- Cukurova University, Faculty of Medicine
-
Ankara, Turquía (Türkiye), 06200
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Turquía (Türkiye), 6560
- Ankara Bilkent Sehir Hastanesi
-
Antalya, Turquía (Türkiye), 07070
- Akdeniz University Medical Faculty
-
Edirne, Turquía (Türkiye), 22030
- Trakya University Medical Faculty
-
Istanbul, Turquía (Türkiye), 34722
- Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
-
Istanbul, Turquía (Türkiye), 34098
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul, Turquía (Türkiye), 34147
- Bakirkoy Training and Research Hospital
-
Izmir, Turquía (Türkiye), 35575
- IEU Medical Point Hospital
-
Kocaeli, Turquía (Türkiye), 41380
- Kocaeli University Medical Faculty
-
-
-
-
-
Cherkasy, Ucrania, 18009
- CNE Clinical Center of Oncology Hematology Transplantology and Palliative Care of the Cherkasy RC
-
Dnipo, Ucrania, 49005
- Ce 'Dnipropetrovsk Regional Clinical Hospital N.A. Mechnikov' of Dnipropetrovsk Rc
-
Dnipro, Ucrania, 49102
- Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
-
Dnipro, Ucrania, 49100
- Municipal Institution 'Clinical Oncology Dispensary' Under Dnipropetrovsk Regional Council
-
Ivano-Frankivsk, Ucrania, 76008
- Ivano-Frankivsk Regional Clinical Hospital
-
Khakhiv, Ucrania, 61070
- Municipal non-profit enterprise 'Regional Center of Oncology'
-
Kharkiv, Ucrania, 61037
- Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval
-
Kyiv, Ucrania, 03115
- State Institution Institute of Urology NAMS of Ukraine based on Kyiv City Clinical Oncology Center
-
Kyiv, Ucrania, 03022
- State Nonprofit Enterprise National Cancer Institute
-
Lviv, Ucrania, 79010
- University Hospital of SNA Danylo Halytsky LMNU
-
Poltava, Ucrania, 36024
- ME 'Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky of the Poltava Regional Council'
-
Uzhhorod, Ucrania, 88000
- Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
HRR gene alteration (as identified by the sponsor's required assays) as follows:
- Cohort 1: positive for HRR gene alteration
- Cohort 2: not positive for DRD (that is, HRR gene alteration)
- Cohort 3: eligible by HRR status
-
Metastatic disease documented by positive bone scan or metastatic lesions on computed tomography (CT) or magnetic resonance imaging (MRI)
-
Metastatic prostate cancer in the setting of castrate levels of testosterone less than or equal to (<=) 50 nanogram per deciliter (ng/dL) on a gonadotropin releasing hormone analog (GnRHa) or bilateral orchiectomy
-
Able to continue GnRHa during the study if not surgically castrate
-
Score of <= 3 on the brief pain inventory-short form (BPI-SF) question number 3 (worst pain in last 24 hours)
Exclusion Criteria:
- Prior treatment with a poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor
- Systemic therapy (that is, novel second-generation AR-targeted therapy such as enzalutamide, apalutamide, or darolutamide; taxane-based chemotherapy, or more than 4 months of abiraterone acetate plus prednisone [AAP] prior to randomization) in the metastatic castration-resistant prostate cancer (mCRPC) setting; or AAP outside of the mCRPC setting
- Symptomatic brain metastases
- History or current diagnosis of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
- Other prior malignancy (exceptions: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) <= 2 years prior to randomization, or malignancy that currently requires active systemic therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cohort 1: Participants with mCRPC and HRR Gene Alteration
Participants with L1 metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alteration will receive combination of niraparib 200 milligrams (mg) or matching placebo and abiraterone acetate (AA) 1000 mg plus prednisone 10 mg. In the open label extension (OLE) phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg. |
Participants will receive niraparib 200 mg capsules or tablets once daily.
Otros nombres:
Participants will receive AA 1000 mg tablets once daily. Participants will receive prednisone 10 mg tablets daily. Participants will receive matching placebo once daily. |
|
Experimental: Cohort 2: Participants with mCRPC and No HRR Gene Alteration
Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg. |
Participants will receive niraparib 200 mg capsules or tablets once daily.
Otros nombres:
Participants will receive AA 1000 mg tablets once daily. Participants will receive prednisone 10 mg tablets daily. Participants will receive matching placebo once daily. |
|
Experimental: Cohort 3 (Open-label): Participants with mCRPC
Participants with mCRPC will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets plus prednisone 10 mg. |
Participants will receive prednisone 10 mg tablets daily. Participants will receive a new formulation of niraparib 200 mg and AA 1000 mg tablets once daily. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Cohort 1: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Periodo de tiempo: Up to 32 months
|
As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by computerized tomography (CT) or magnetic resonance imaging (MRI) as per response evaluation criteria in solid tumors (RECIST) 1.1; (2) Progression of bone lesions observed by bone scan based on prostate cancer working group 3 (PCWG3) criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan greater than or equal to (>=) 6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan >=2 new lesions indicate progression; scan does not show >=2 new lesions means no progression. If Week 8 scan less than (<) 2 new bone lesions compared to baseline, the initial scan >=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan >=6 weeks later. |
Up to 32 months
|
|
Cohort 1 Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-Free Survival (rPFS) as Assessed by Blinded Independent Central Review (BICR)
Periodo de tiempo: Up to 32 months
|
As per BICR, rPFS is time interval from the date of randomization to radiographic progression or death, whichever occurred first. Radiographic progression was determined by: (1) progression of soft tissue lesions measured by CT or MRI as per RECIST 1.1; (2) Progression of bone lesions observed by bone scan based on PCWG3 criteria. PCWG3 criteria: bone progression was confirmed by subsequent scan >=6 weeks later. Week 8 scan was baseline to which all subsequent scans were compared to determine progression. Confirmatory scan >=2 new lesions indicate progression; scan does not show >=2 new lesions means no progression. If Week 8 scan <2 new bone lesions compared to baseline, the initial scan >=2 new lesions compared to Week 8 scan indicates progression if confirmed by subsequent scan >=6 weeks later. |
Up to 32 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Cohorte 1: Supervivencia general (SG)
Periodo de tiempo: Hasta 97 meses
|
Hasta 97 meses
|
|
Cohorte 1: tiempo hasta la progresión sintomática
Periodo de tiempo: Hasta 97 meses
|
Hasta 97 meses
|
|
Cohorte 1: tiempo hasta el inicio de la quimioterapia citotóxica
Periodo de tiempo: Hasta 97 meses
|
Hasta 97 meses
|
|
Concentraciones plasmáticas observadas de niraparib
Periodo de tiempo: Hasta 97 meses
|
Hasta 97 meses
|
|
Concentraciones plasmáticas observadas de abiraterona
Periodo de tiempo: Hasta 97 meses
|
Hasta 97 meses
|
|
Número de participantes con eventos adversos emergentes del tratamiento (TEAE)
Periodo de tiempo: Hasta 96 meses
|
Hasta 96 meses
|
|
Número de participantes con eventos adversos surgidos del tratamiento por gravedad
Periodo de tiempo: Hasta 96 meses
|
Hasta 96 meses
|
|
Número de participantes con anomalías en los valores de laboratorio
Periodo de tiempo: Hasta 96 meses
|
Hasta 96 meses
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publicaciones y enlaces útiles
Publicaciones Generales
- Roubaud G, Attard G, Boegemann M, Olmos D, Trevisan M, Antoni L, Pascoe K, Capone C, Van Sanden S, Hashim M, Palmer S, Chi K. Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancer. Eur J Cancer. 2024 Sep;209:114183. doi: 10.1016/j.ejca.2024.114183. Epub 2024 Jun 17.
- Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S; MAGNITUDE Principal Investigators. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023 Jun 20;41(18):3339-3351. doi: 10.1200/JCO.22.01649. Epub 2023 Mar 23.
- Rathkopf DE, Roubaud G, Chi KN, Efstathiou E, Attard G, Olmos D, Small EJ, Saad M, Castro E, Kim W, Wu D, Bertzos K, Dibaj S, Zhang J, Francis P, Smith MR. Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. Eur Urol. 2025 Oct;88(4):359-369. doi: 10.1016/j.eururo.2024.09.003. Epub 2024 Sep 23.
- De Santis M, Breijo SM, Robinson P, Capone C, Pascoe K, Van Sanden S, Hashim M, Trevisan M, Daly C, Reitsma F, van Beekhuizen S, Ruan H, Heeg B, Verzoni E. Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer. Adv Ther. 2024 Aug;41(8):3039-3058. doi: 10.1007/s12325-024-02918-6. Epub 2024 Jul 3.
- Ye D, Saad M, Lee JY, Jung W, Pang ST, Li L, Gurney H, Attard G, Chi KN, Mundle S, Zhuo J, Singh A, Lin Y, Sandhu S. Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study. Int J Urol. 2026 Apr;33(4):e70455. doi: 10.1111/iju.70455.
- Russu A, Hazra A, Tian H, Haddish-Berhane N, Perez Ruixo JJ, Boulton M. Population Pharmacokinetics of Niraparib/Abiraterone Acetate Administered as Single-Agent Combination and Dual-Acting Tablets Plus Prednisone for Metastatic Castration-Resistant Prostate Cancer. Adv Ther. 2025 Apr;42(4):1860-1880. doi: 10.1007/s12325-025-03104-y. Epub 2025 Feb 28.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Neoplasias prostáticas resistentes a la castración
- Compuestos policíclicos
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Madreadiediols
- Androstenes
- Androstanes
- Acetato de abiraterona
- Prednisona
- niraparib
Otros números de identificación del estudio
- CR108534
- 2017 (Subvención/contrato del NIH de EE. UU.)
- 2017-003364-12 (Número EudraCT)
- 64091742PCR3001 (Otro identificador: Janssen Research & Development, LLC)
- 2023-503254-12-00 (Identificador de registro: EUCT number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .